Arcus Biosciences (RCUS) PT Raised to $40 at Goldman Sachs
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
Goldman Sachs raised its price target on Arcus Biosciences (NYSE: RCUS) to $40.00 (from $36.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Altium Ltd. (ALU:AU) (ALMFF) PT Raised to AUD42 at Credit Suisse
- Telecom Italia SpA (TIT:IM) (TI) PT Raised to EUR0.52 at JPMorgan
- Domino's Pizza Enterprises Ltd. (DMP:AU) (DPZUF) PT Lowered to AUD70.71 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!